Bill > S832

This bill, known as the EPIC Act of 2025 (Ensuring Pathways to Innovative Cures Act of 2025), amends the Social Security Act to modify the negotiation period for drug price negotiations, specifically targeting the timeline for small-molecule and biologic drug candidates. Currently, the law requires at least 7 years to have passed since a drug's approval before it can be subject to price negotiations. The bill introduces a phased approach: for the initial price applicability years of 2026 and 2027, the existing 7-year period remains in place, but starting in 2028 and subsequent years, the negotiation period will be modified. While the exact new number of years is not specified in the provided text, the bill indicates a change is intended to equalize the negotiation periods between different types of drugs (small-molecule and biologic). This adjustment could potentially impact how and when certain drugs become eligible for government price negotiations, which may have implications for pharmaceutical companies and drug pricing strategies.

Budget and Finance

https://www.congress.gov/bill/119th-congress/senate-bill/832/all-info